2fmg: Difference between revisions
From Proteopedia
Jump to navigationJump to search
No edit summary |
No edit summary |
||
| Line 1: | Line 1: | ||
[[Image:2fmg. | {{Seed}} | ||
[[Image:2fmg.png|left|200px]] | |||
<!-- | <!-- | ||
| Line 9: | Line 10: | ||
{{STRUCTURE_2fmg| PDB=2fmg | SCENE= }} | {{STRUCTURE_2fmg| PDB=2fmg | SCENE= }} | ||
===Carbonic anhydrase activators. Activation of isoforms I, II, IV, VA, VII and XIV with L- and D- phenylalanine and crystallographic analysis of their adducts with isozyme II: sterospecific recognition within the active site of an enzyme and its consequences for the drug design, structure with L-phenylalanine=== | |||
<!-- | |||
The line below this paragraph, {{ABSTRACT_PUBMED_16686544}}, adds the Publication Abstract to the page | |||
(as it appears on PubMed at http://www.pubmed.gov), where 16686544 is the PubMed ID number. | |||
--> | |||
{{ABSTRACT_PUBMED_16686544}} | |||
==About this Structure== | ==About this Structure== | ||
| Line 29: | Line 33: | ||
[[Category: Activator]] | [[Category: Activator]] | ||
[[Category: Carbonic anhydrase ii]] | [[Category: Carbonic anhydrase ii]] | ||
''Page seeded by [http://oca.weizmann.ac.il/oca OCA ] on | |||
''Page seeded by [http://oca.weizmann.ac.il/oca OCA ] on Sat Jul 5 16:23:22 2008'' | |||
Revision as of 13:23, 5 July 2008
Carbonic anhydrase activators. Activation of isoforms I, II, IV, VA, VII and XIV with L- and D- phenylalanine and crystallographic analysis of their adducts with isozyme II: sterospecific recognition within the active site of an enzyme and its consequences for the drug design, structure with L-phenylalanine
Template:ABSTRACT PUBMED 16686544
About this Structure
2FMG is a Single protein structure of sequence from Homo sapiens. Full crystallographic information is available from OCA.
Reference
Carbonic anhydrase activators. Activation of isoforms I, II, IV, VA, VII, and XIV with L- and D-phenylalanine and crystallographic analysis of their adducts with isozyme II: stereospecific recognition within the active site of an enzyme and its consequences for the drug design., Temperini C, Scozzafava A, Vullo D, Supuran CT, J Med Chem. 2006 May 18;49(10):3019-27. PMID:16686544
Page seeded by OCA on Sat Jul 5 16:23:22 2008